Indegene Beneish M-Score Historical Data
The historical data trend for Indegene's Beneish M-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Indegene Beneish M-Score Chart
|
Indegene Annual Data
|
|
Trend |
Mar21 |
Mar22 |
Mar23 |
| Beneish M-Score |
|
- |
- |
-1.24 |
|
Indegene Quarterly Data
|
|
Mar21 |
Mar22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
Jun24 |
Sep24 |
| Beneish M-Score |
Get a 7-Day Free Trial
|
|
- |
- |
- |
- |
- |
Competitive Comparison of Indegene's Beneish M-Score
For the Health Information Services subindustry, Indegene's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Indegene's Beneish M-Score Distribution in the Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Indegene's Beneish M-Score distribution charts can be found below:
* The bar in red indicates where Indegene's Beneish M-Score falls into.
Indegene Beneish M-Score Calculation
The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.
The M-Score Variables:
The M-score of Indegene for today is based on a combination of the following eight different indices:
| M | = | -4.84 | + | 0.92 * DSRI | + | 0.528 * GMI | + | 0.404 * AQI | + | 0.892 * SGI | + | 0.115 * DEPI |
| = | -4.84 | + | 0.92 * 1.0646 | + | 0.528 * 1 | + | 0.404 * 2.5811 | + | 0.892 * 1.3854 | + | 0.115 * 1.0442 |
| - | 0.172 * SGAI | + | 4.679 * TATA | - | 0.327 * LVGI |
| - | 0.172 * 1.1373 | + | 4.679 * 0.061656 | - | 0.327 * 1.2283 |
| = | -1.24 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
| This Year (Mar23) TTM: | Last Year (Mar22) TTM: |
Total Receivables was ₹6,563 Mil.
Revenue was ₹23,061 Mil.
Gross Profit was ₹23,061 Mil.
Total Current Assets was ₹14,487 Mil.
Total Assets was ₹22,039 Mil.
Property, Plant and Equipment(Net PPE) was ₹1,518 Mil.
Depreciation, Depletion and Amortization(DDA) was ₹598 Mil.
Selling, General, & Admin. Expense(SGA) was ₹858 Mil.
Total Current Liabilities was ₹4,891 Mil.
Long-Term Debt & Capital Lease Obligation was ₹4,795 Mil.
Net Income was ₹2,661 Mil.
Gross Profit was ₹0 Mil.
Cash Flow from Operations was ₹1,302 Mil.
|
Total Receivables was ₹4,449 Mil.
Revenue was ₹16,646 Mil.
Gross Profit was ₹16,646 Mil.
Total Current Assets was ₹11,300 Mil.
Total Assets was ₹13,535 Mil.
Property, Plant and Equipment(Net PPE) was ₹799 Mil.
Depreciation, Depletion and Amortization(DDA) was ₹335 Mil.
Selling, General, & Admin. Expense(SGA) was ₹545 Mil.
Total Current Liabilities was ₹4,404 Mil.
Long-Term Debt & Capital Lease Obligation was ₹439 Mil.
|
1. DSRI = Days Sales in Receivables Index
Measured as the ratio of Revenue in Total Receivables in year t to year t-1.
A large increase in DSR could be indicative of revenue inflation.
| DSRI | = | (Receivables_t / Revenue_t) | / | (Receivables_t-1 / Revenue_t-1) |
| = | (6562.66 / 23061.33) | / | (4449.48 / 16646.09) |
| = | 0.284574 | / | 0.267299 |
| | = | 1.0646 |
2. GMI = Gross Margin Index
Measured as the ratio of gross margin in year t-1 to gross margin in year t.
Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.
| GMI | = | GrossMargin_t-1 | / | GrossMargin_t |
| = | (GrossProfit_t-1 / Revenue_t-1) | / | (GrossProfit_t / Revenue_t) |
| = | (16646.09 / 16646.09) | / | (23061.33 / 23061.33) |
| = | 1 | / | 1 |
| | = | 1 |
3. AQI = Asset Quality Index
AQI is the ratio of asset quality in year t to year t-1.
Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.
| AQI | = | (1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) | / | (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1) |
| = | (1 - (14487.06 + 1517.76) / 22038.66) | / | (1 - (11300.25 + 798.79) / 13534.69) |
| = | 0.273784 | / | 0.106072 |
| | = | 2.5811 |
4. SGI = Sales Growth Index
Ratio of Revenue in year t to sales in year t-1.
Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.
| SGI | = | Sales_t | / | Sales_t-1 |
| = | Revenue_t | / | Revenue_t-1 |
| = | 23061.33 | / | 16646.09 |
| | = | 1.3854 |
5. DEPI = Depreciation Index
Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.
DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.
| DEPI | = | (Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) | / | (Depreciation_t / (Depreciaton_t + PPE_t)) |
| = | (334.51 / (334.51 + 798.79)) | / | (598.1 / (598.1 + 1517.76)) |
| = | 0.295165 | / | 0.282675 |
| | = | 1.0442 |
Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.
6. SGAI = Sales, General and Administrative expenses Index
The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.
SGA expenses index > 1 means that the company is becoming less efficient in generate sales.
| SGAI | = | (SGA_t / Sales_t) | / | (SGA_t-1 /Sales_t-1) |
| = | (858.09 / 23061.33) | / | (544.61 / 16646.09) |
| = | 0.037209 | / | 0.032717 |
| | = | 1.1373 |
7. LVGI = Leverage Index
The ratio of total debt to Total Assets in year t relative to yeat t-1.
An LVGI > 1 indicates an increase in leverage
| LVGI | = | ((LTD_t + CurrentLiabilities_t) / TotalAssets_t) | / | ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1) |
| = | ((4795.37 + 4891.46) / 22038.66) | / | ((438.75 + 4404.39) / 13534.69) |
| = | 0.439538 | / | 0.357832 |
| | = | 1.2283 |
8. TATA = Total Accruals to Total Assets
Total accruals calculated as the change in working capital accounts other than cash less depreciation.
| TATA | = | (IncomefromContinuingOperations_t | - | CashFlowsfromOperations_t) | / | TotalAssets_t |
| = | (NetIncome_t - NonOperatingIncome_t | - | CashFlowsfromOperations_t) | / | TotalAssets_t |
| = | (2660.99 - 0 | - | 1302.18) | / | 22038.66 |
| | = | 0.061656 |
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
Indegene has a M-score of -1.24 signals that the company is likely to be a manipulator.
Indegene Business Description
Traded in Other Exchanges
Address
Outer Ring Road, Aspen Block G4, 3rd Floor, Manyata Embassy Business Park, Nagawara, Bengaluru, KA, IND, 560045
Indegene Ltd provides digital-led commercialization services for the life sciences industry, including biopharmaceutical, emerging biotech, and medical devices companies, that assist them with drug development and clinical trials, regulatory submissions, pharmacovigilance and complaints management, and the sales and marketing of their products. Its portfolio of solutions covers all aspects of commercial, medical, regulatory, and R&D operations of life sciences companies. The company segment includes Enterprise Medical Solutions, Enterprise Commercial Solutions, Omnichannel Activation, and Others. Key revenue is generated from the Omnichannel Activation segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NSE:INDGN has been successfully added to your